
|Articles|July 26, 2002
Flexible light-based system gets FDA nod
TheraLight received clearance from the U.S. Food and Drug Administrationto market its UV120-2 UVA/UUVB Phototherapy System for the treatment ofpsoriasis, vitiligo, atopic dermatitis and seborrheic dermatitis.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Grants Breakthrough Therapy Designation to Litifilimab for Cutaneous Lupus Erythematosus
2
Del Rosso's What's New in the Medicine Chest 2026: CHE, CSU, and Vitiligo
3
Multi-Ingredient Topical Treatment Significantly Improves Wrinkles and Skin Thickness in Patients with "Ozempic Face"
4
Beyond Weight Loss: Clinical Perspectives on GLP-1s for Inflammatory Dermatoses
5










